# Congressional Researchers Call Out FDA For Missing Deadline To Publish Cannabinoid … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/congressional-researchers-call-out-fda-for-missing-deadline-to-publish-cannabinoid/ > **Published:** 2026-06-16T10:46:47-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:52:19-04:00 > **Clinical Summary:** FDA cannabinoid standards delay impacts clinical cannabis practice. Clinician guidance on product assessment without federal guidelines. --- ✦ New CED Clinical Relevance #52 [Clinical Context](https://cedclinic.com/cannabis-hyperemesis-syndrome-treatment-insights-2026/) Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. PolicyResearchIndustrySafetyPainAnxietyMental Health Clinical Summary Congressional researchers have criticized the FDA for failing to meet its deadline to publish comprehensive guidance on [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) standards, a regulatory gap that has left the agency without clear frameworks for evaluating cannabis products entering the marketplace. The FDA’s delay in developing standardized lists and research protocols for cannabinoids has created uncertainty around product quality, potency labeling, and safety assessment across states with legal cannabis programs. Without established federal [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) standards, clinicians lack reliable data on the chemical composition and bioavailability of products their patients may be using, complicating evidence-based counseling and drug interaction assessments. The Congressional call for action reflects growing recognition that cannabis products require the same rigorous oversight as other therapeutic agents, particularly as more patients and providers incorporate cannabis into treatment plans. This regulatory gap also affects manufacturers and dispensaries, who operate without clear federal standards for product characterization and quality control. Clinicians should document their patients’ specific cannabis products with attention to reported cannabinoid profiles and remain vigilant for emerging FDA guidance that may eventually provide standardized information to support more informed prescribing decisions. Dr. Caplan’s Take “The FDA’s delayed cataloging of cannabinoid compounds is a genuine problem for clinical practice, because without systematic characterization we’re making treatment decisions in a fog of incomplete pharmacology and variable product quality. Until we have standardized, peer-reviewed data on safety and efficacy across the cannabinoid spectrum, I tell my patients we’re working with clinical signals rather than established evidence.” Clinical Perspective ⚕️ The FDA’s delayed publication of [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) findings represents a significant gap in the regulatory infrastructure that clinicians rely on to counsel patients about cannabis products. Without comprehensive federal guidance on [cannabinoid safety](https://cedclinic.com/federal-hemp-thc-ban-delay-vote-next-week/), efficacy, and standardization, providers are left navigating a fragmented landscape where product quality, potency, and composition vary substantially across jurisdictions and manufacturers. This regulatory lag is particularly problematic given the growing number of patients asking about cannabis for symptom management, as clinicians cannot reference unified, evidence-based government standards to inform prescribing decisions or patient counseling. The complexity is compounded by the fact that most cannabis products lack rigorous clinical trial data, making it difficult to distinguish between marketing claims and genuine therapeutic benefit. Practically, clinicians should continue to obtain detailed product information from patients (including cannabinoid ratios, source, and testing results where available), document conversations about [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in medical records, and remain transparent about the 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Congressional%20Researchers%20Call%20Out%20FDA%20For%20Missing%20Deadline%20To%20Publish%20Cannabinoid%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59323)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59323)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Congressional%20Researchers%20Call%20Out%20FDA%20For%20Missing%20Deadline%20To%20Publish%20Cannabinoid%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59323)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [CED Digest: 230 Items — March 18, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) - [CED Digest: 239 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-digest-march-17-2026/) - [CED Digest: 230 Items — March 17, 2026](https://cedclinic.com/cannabis-clinical-research-digest-march-2026/) 📰 Source: [https://www.marijuanamoment.net/congressional-researchers-call-out-fda-for-missing-deadline-to-publish-cannabinoid-list-and-define-hemp-containers/](https://www.marijuanamoment.net/congressional-researchers-call-out-fda-for-missing-deadline-to-publish-cannabinoid-list-and-define-hemp-containers/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).